How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/allogeneic-peripheral-blood-stem-cell-transplant.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Allogeneic peripheral blood stem cell transplant — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Allogeneic peripheral blood stem cell transplant (disease) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Allogeneic peripheral blood stem cell transplant, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Trecondi	TREOSULFAN	Medexus	treosulfan		2019-01-01
Neulasta	Pegfilgrastim-Apgf	Amgen	Colony-stimulating factor	G-CSF receptor on hematopoietic cells	2002-01-01
Neulasta	PEGFILGRASTIM	Amgen	Leukocyte Growth Factor [EPC]	Granulocyte colony-stimulating factor receptor	2002-01-01
FULPHILA	PEGFILGRASTIM-JMDB	MYLAN GMBH	Leukocyte Growth Factor [EPC]	Granulocyte colony-stimulating factor receptor
Neulasta	Neulasta	Columbia University		Granulocyte colony-stimulating factor receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Amgen · 2 drugs in Allogeneic peripheral blood stem cell transplant
Columbia University · 1 drug in Allogeneic peripheral blood stem cell transplant
MYLAN GMBH · 1 drug in Allogeneic peripheral blood stem cell transplant
Medexus · 1 drug in Allogeneic peripheral blood stem cell transplant

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Allogeneic peripheral blood stem cell transplant:

Cite this brief

Drug Landscape (2026). Allogeneic peripheral blood stem cell transplant — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/allogeneic-peripheral-blood-stem-cell-transplant. Accessed 2026-06-10.

Allogeneic peripheral blood stem cell transplant full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing